KAAN ÇEYLAN, TEKİN KARSLIGİL, FEYZA NUR AŞKIN, GÜLSÜM KAYA ÖZEN
Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi - 2023;18(1):115-119
Objective:The COVID-19 pandemic caused by SARS-CoV-2 has increased its impact since the day it started, infecting millions of people around the world and causing serious deaths.The fact that an effective and definitive treatment or prophylaxis method has not yet been found has increased the importance of vaccine studies.As of January 14, 2021, CoronaVac (Sinovac) and Pfizer-Biontech vaccines have been started to be administered to all citizens, starting from healthcare professionals in our country. In this study, the efficacy of these two vaccines, which are actively applied in our country, was evaluated. Method:Eighty-four volunteers who had not previously experienced COVID-19 by clinical, radiological or PCR method were included in the study.Serum samples were taken from the volunteers before the vaccine administration and 1 month after the first dose of vaccine administration.SARS-CoV-2 IgG levels were measured from the serum samples taken by ELISA method and examined in terms of the efficacy of two different vaccines. Result:84 volunteers, including 39 women and 45 men, were included in the study; 50 volunteers preferred CoronaVac (Sinovac) and 34 volunteers preferred Pfizer-Biontech vaccine. Pre-vaccine SARS-CoV-2 IgG antibody titers of 13 volunteers administered CoronaVac (Sinovac) vaccine and 4 volunteers administered Pfizer-Biontech vaccine were positive.Of the volunteers whose pre-vaccination SARS-CoV-2 IgG antibody titers were negative; Seropositivity rate was 67.6% (25/37) in those who received a single dose of CoronaVac (Sinovac) vaccine, and 100% (30/30) in those who received a single dose of Pfizer-Biontech vaccine. Conclusion: Pre-vaccine seropositivity was detected in 17 (20.2%) of the volunteers participating in the study. Of the volunteers who were seronegative before the study; 67.6% of those vaccinated with CoronaVac-Sinovac; Post-vaccine seropositivity developed in 100% of those vaccinated with Pfizer-Biontech. In the study, it is seen that the Pfizer-Biontech vaccine induces the immune system better after a single dose vaccination.
